Cagayan De Oro ‘Traslacion’ Draws 13K

Sa taunang “Traslacion,” higit sa 13,000 deboto ang nagpakita ng kanilang debosyon kay Jesus Nazareno.

Siargao’s Sugba Lagoon To Close For A Month

Isasara ang makikita sa Sugba Lagoon simula Enero 10, 2025 para sa environmental recovery. Maging responsable tayo sa ating kalikasan.

Surigao City Becomes Hub For World Cruisers

Ipinakilala ang Surigao City bilang sentro ng clearance para sa mga internasyonal na cruiser sa mga yate.

Antique Town’s New PHP5 Million Greenhouse Will Secure High-Value Crop Supply

PHP5 milyong proyekto sa Libertad para sa mas mataas na produksyon ng pananim. Isang hakbang patungo sa mas masaganang kinabukasan.

Fujitsu Gives Free Access To Intellectual Property Rights For Fight Against COVID-19

Fujitsu Limited commits to the "Open COVID Pledge," which promotes free access to participants' intellectual property rights for activities aimed at ending the global spread of the disease.
By The Mindanao Life

Fujitsu Gives Free Access To Intellectual Property Rights For Fight Against COVID-19

6
6

How do you feel about this story?

Like
Love
Haha
Wow
Sad
Angry

Fujitsu Limited today announced that as part of its ongoing efforts to mitigate the social and economic impacts of the COVID-19 pandemic, it will commit to the “Open COVID Pledge,” which promotes free access to participants’ intellectual property rights for activities aimed at ending the global spread of the disease.

In committing to the Open COVID Pledge, which originated in the US, Fujitsu has declared that it will not assert its patents, utility models, or designs against individuals or entities for a certain period of time and will not seek any consideration or compensation for such activities. Fujitsu has also endorsed and declared its involvement with the “OPEN COVID-19 DECLARATION,” a similar initiative in Japan.

Through its commitment to these pledges, Fujitsu will contribute decisively to an early end to the spread of the COVID-19 pandemic by providing free access to approximately 40,000 patents, utility models, design patents (including pending applications) related to the development of new drugs and patient care, and actively promote cross-industry utilization by companies and research institutions around the world in the spirit of global cooperation and human centric innovation.